Year-over-year earnings per share growth for the last twelve months: hoththerapeutics.com (HOTH)

Hoth Therapeutics Inc. - graphic logo of issuer HOTH

Hoth Therapeutics, Inc. (HOTH) is facing rising costs as it expands R&D testing. Geopolitical tensions and sanctions are hindering the international certification of dermatological products. However, patents and contract manufacturing promise global reach. On GURU.Markets, the quarterly dynamics of net income per share are assigned the value 37.10, allowing for the tracking of the company's internal imbalances prior to the publication of reports.

Hoth Therapeutics (HOTH) - Year-over-year earnings per one share growth for the last 12 months from 07/04/2022 to 05/28/2026

hoththerapeutics.com - analytical breakdowns and key metrics (HOTH)

- company stock exchange capitalization indicators:
Summary company analytics:hoththerapeutics.com, HOTH
Finished products of Hoth Therapeutics, Inc.

Hoth Therapeutics, Inc. (HOTH) is optimizing costs by outsourcing drug development and clinical trials to external contractors to concentrate on therapies for dermatological pathologies. The current value of 37.10 reflects the dynamics of net earnings per share, allowing the separation of speculative noise from the real fundamental signal, which, when analyzing the quarterly earnings per share growth rate, helps investors avoid overpaying for the asset.

Who Hoth Therapeutics, Inc. competes with

KRYS: Quarterly EPS earnings growth|APGE - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Arcutis Biotherapeutics, Inc.|Year-over-year earnings per share growth for the last 12 months VCEL (Vericel)|Year-over-year earnings per share growth for the last twelve months Oruka Pharma (ORKA)|Year-over-year net earnings per share change for the last twelve months Sanara MedTech|Quarterly EPS earnings growth DBVT (DBV Technologies SA)|Solesence Inc (SLSN) - Earnings per share growth in annualized terms for the last twelve months|DERM: Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months FBRX (Forte Biosciences)|Empro Group (EMPG) - Year-over-year earnings per share growth for the last twelve months|Net earnings per share growth for the trailing year Sol-Gel Technologies Ltd. SLGL|Year-over-year net earnings per share growth for the last 12 months AXIL|Year-over-year net earnings per share growth for the last 12 months Medicus Pharma Ltd. (MDCX)|Quarterly EPS earnings growth VRCA|BFRI - Earnings per share growth in annualized terms for the last twelve months|Quarterly EPS earnings growth VYNE (VYNE Therapeutics)|Year-over-year earnings per one share growth for the last 12 months SNOA|Quoin Pharmaceuticals Ltd. - Quarterly EPS earnings growth|Year-over-year net earnings per share change for the last twelve months Azitra Corporation AZTR|DRMA (Dermata) - Year-over-year net earnings per share growth for the last 12 months|Elevai Labs Inc. (ELAB) - Quarterly EPS earnings growth|RVNC (Revance Therapeutics, Inc.) - Quarterly EPS earnings growth